195 related articles for article (PubMed ID: 20357493)
41. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
Resino S; Palladino C; Lorente R; Micheloud D; Bellón JM; Larru B; Gutiérrez MD; de José MI; Polo R; Muñoz-Fernández MA;
Pediatr Infect Dis J; 2010 Aug; 29(8):774-7. PubMed ID: 20375850
[TBL] [Abstract][Full Text] [Related]
42. Antiretroviral therapy in HIV-1 infected children.
Lodha R; Upadhyay A; Kabra SK
Indian Pediatr; 2005 Aug; 42(8):789-96. PubMed ID: 16141480
[TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control but school failure.
Souza E; Santos N; Valentini S; Silva G; Falbo A
J Trop Pediatr; 2010 Dec; 56(6):421-6. PubMed ID: 20167634
[TBL] [Abstract][Full Text] [Related]
44. Long term outcomes of nevirapine containing antiretroviral therapy at a center in Thailand.
Htun WL; Bowonwatanuwong C; Phonrat B; Pitisuttithum P
Southeast Asian J Trop Med Public Health; 2012 Jul; 43(4):860-70. PubMed ID: 23077808
[TBL] [Abstract][Full Text] [Related]
45. Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less.
Ferrer E; Santamariña E; Domingo P; Fumero E; Ribera E; Knobel H; Lopez JC; Barrios A; Podzamczer D
AIDS; 2004 Aug; 18(12):1727-9. PubMed ID: 15280785
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.
Huerta García G; Mata-Marín JA; Domínguez-Hermosillo JC; Chavez-García M; Banda-Lara MI; Nuñez-Rodríguez N; Cruz-Herrera JE; Sandoval-Ramírez JL; Villagómez-Ruiz A; Manjarrez-Tellez B; Gaytan-Martínez JE
J Infect Dev Ctries; 2016 Jun; 10(6):605-11. PubMed ID: 27367009
[TBL] [Abstract][Full Text] [Related]
47. [The evaluation of four-year highly active antiretroviral therapy in HIV-1 infected patients].
Deng XJ; He Y; Yang L; Zou SP; Yang H; Zheng YH
Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):230-4. PubMed ID: 21600088
[TBL] [Abstract][Full Text] [Related]
48. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
Gonzalez-Tome MI; Amador JT; Peña MJ; Gomez ML; Conejo PR; Fontelos PM
BMC Infect Dis; 2008 Oct; 8():144. PubMed ID: 18945352
[TBL] [Abstract][Full Text] [Related]
49. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B;
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Kesselring AM; Wit FW; Sabin CA; Lundgren JD; Gill MJ; Gatell JM; Rauch A; Montaner JS; de Wolf F; Reiss P; Mocroft A;
AIDS; 2009 Aug; 23(13):1689-99. PubMed ID: 19487907
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
[TBL] [Abstract][Full Text] [Related]
52. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.
Kiselinova M; Geretti AM; Malatinkova E; Vervisch K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
J Antimicrob Chemother; 2015 Dec; 70(12):3311-6. PubMed ID: 26324076
[TBL] [Abstract][Full Text] [Related]
53. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
Monteiro P; Perez I; Pich J; Gatell JM; Martínez E
J Antimicrob Chemother; 2013 Feb; 68(2):404-8. PubMed ID: 23109185
[TBL] [Abstract][Full Text] [Related]
54. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
[TBL] [Abstract][Full Text] [Related]
55. Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.
Chohan BH; Tapia K; Benki-Nugent S; Khasimwa B; Ngayo M; Maleche-Obimbo E; Wamalwa D; Overbaugh J; John-Stewart G
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):783-91. PubMed ID: 25819584
[TBL] [Abstract][Full Text] [Related]
56. Predictors of treatment failure in Cambodian children with human immunodeficiency virus infection.
Beldjebel I; Vujcikova J; Sokolova J; Krcmery V
Pediatr Infect Dis J; 2010 Jun; 29(6):580-1; author reply 581. PubMed ID: 20508485
[No Abstract] [Full Text] [Related]
57. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine.
Rodríguez-Arrondo F; Aguirrebengoa K; Portu J; Muñoz J; García MA; Goikoetxea J; Martínez E; Iribarren JA; Perez-Alvarez N; Negredo E; Clotet B
Curr HIV Res; 2009 Sep; 7(5):526-32. PubMed ID: 19925403
[TBL] [Abstract][Full Text] [Related]
58. Once-a-day (QD) vs. twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction.
Maserati R; Brandolini M; Cattelan A; Orani A; Sighinolfi L; Andreoni M; Uglietti A; Guaraldi G; Sotgiu G;
Curr HIV Res; 2011 Apr; 9(3):166-73. PubMed ID: 21443516
[TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine.
Sabin CA; Fisher M; Churchill D; Pozniak A; Hay P; Easterbrook P; Williams I
J Acquir Immune Defic Syndr; 2001 Apr; 26(5):462-5. PubMed ID: 11391166
[TBL] [Abstract][Full Text] [Related]
60. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
